Samsung BioLogics approved to make first mAb for US market

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Mirror-images)
(Image: Getty/Mirror-images)

Related tags: Samsung biologics, Monoclonal antibodies, Fda

Samsung BioLogics announced license-approval by the US FDA to create a mAb drug product at its Plant 1 facility.

The US Food and Drug Administration’s (FDA) approval for Samsung BioLogics to create a complete drug product, a monoclonal antibody (mAb), is the first such approval the company has received from the authority. It joins an earlier approval by Japan’s Pharmaceuticals and Medical Devices Agency for a single drug product and two drug product approvals by the European Medicines Agency.

Samsung BioLogics did not reveal the name of the product that will be manufactured, nor its client, but the decision follows on from the FDA’s first approval of the production of a mAb drug substance, in February 2017​.

TH Kim, CEO and President of Samsung BioLogics, said in a statement​: “Samsung BioLogics continues to prove that it possesses the capability to provide end-to-end service from cell line development to fill/finish DP service…Samsung BioLogics will keep innovating ourselves to manufacture high-quality biologics products for clients all over the world in a timely manner”.

The contract development and manufacture organisation (CDMO) is now building a roster of substances and products it can produce across its two sites, with a third site completed but not yet validated​. It has a total of 16 global approvals for drug substances and is rapidly growing its manufacturing base​.

However, despite the good news of the approval, there is still an accounting probe​ hanging over the company. The most serious charge against the company, on the breach of accounting rules, has been delayed until South Korea’s Financial Supervisory Service has produced an audit report.

At the time of publishing, Samsung BioLogics had not replied to correspondence requesting comment.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more